Cilostazol significantly reduced major adverse cardiac events (RR 0.71) in aspirin-intolerant patients following percutaneous coronary intervention.
Does cilostazol reduce major adverse cardiac events in patients undergoing percutaneous coronary intervention with aspirin intolerance?
Cilostazol may be an effective alternative antiplatelet agent that reduces major adverse cardiac events in aspirin-intolerant patients undergoing PCI.
Absolute Event Rate: 0% vs 0%
Aspirin (ASA) is commonly used in dual antiplatelet therapy (DAPT) of patients undergoing percutaneous coronary intervention. The pharmacologic management in the patient demographic with an ASA intolerance is poorly defined. This study aims to determine the efficacy and safety of the phosphodiesterase-3 inhibitor, cilostazol, as an alternative DAPT for ASA-intolerant patients. We used PubMed, Google Scholar, and Cochrane until January 2024 to identify all related prospective and retrospective studies evaluating cilostazol antiplatelet therapy in ASA-intolerant patients. Studies that did not include the target population were excluded. Fixed and random effect models with the Mantel-Haenszel statistical method were used to calculate P values, risk ratios, Z scores, and a 95% confidence interval on RevMan 7.14.0 software. Cilostazol use demonstrates a significant decrease in the incidence of major adverse cardiac events (P = 0.02) (relative risk RR = 0.71 0.53, 0.94). A nonsignificant trend for benefit was identified for incidence of myocardial infarction (P = 0.34) (RR = 0.42 0.07, 2.46) and major bleeding event (P = 0.71) (RR = 0.65 0.07, 6.37). The findings of this study suggest a potential benefit for the use of cilostazol in patients after percutaneous coronary intervention with aspirin intolerance.
Mootz et al. (Tue,) reported a other. Cilostazol significantly reduced major adverse cardiac events (RR 0.71) in aspirin-intolerant patients following percutaneous coronary intervention.